Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14346802 | 0.90 | APP (0.63) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3181774 | 0.87 | APP (0.71) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3181750 | 0.81 | APP (0.70) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3193416 | 0.80 | APP (1.00) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3198654 | 0.79 | APP (0.71) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3187032 | 0.78 | APP (0.70) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3197429 | 0.77 | APP (0.77) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3188005 | 0.76 | APP (1.00) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3192613 | 0.76 | APP (0.84) | APPNPC1RAB9ASMN1; SMN2TLR7 | |
| SCHEMBL3188475 | 0.76 | APP (0.62) | APPNPC1RAB9ASMN1; SMN2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035418-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | claimed |
| WO-2007149030-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| US-7670591-B2 | Heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7670591-B2 | Heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7670591-B2 | Heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| EP-2035418-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007149030-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | PSEN1, PSEN2, APP | APP 3/4885NPC1 293/4885RAB9A 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.